Developer of a botulinum toxin liquid formulation designed to bring a new anti-aging and medical experience characterized by efficacy. Revelyx Bio is based in DE and was founded in 2025. Its last reported valuation was $110 million in Jan 2026. It has raised $10.4 million.
Last reported valuation
$109.5M
Oct 2026
Priced at
—
Total raised
$10.4M
Last round
—
Cap table — not yet on record
Revelyx Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Revelyx Bio with a free account
·Watch Revelyx Bio: the Monday email on marks, rounds and moves
